ASTS
AST SpaceMobile, Inc.
ASTS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
MYSE
Myseum Inc.
There isn't enough reported data to score MYSE yet.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MYSE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
MYSE's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
MYSE PE Valuation
MYSE has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
MYSE Forward outlook
There aren't enough analyst estimates for MYSE to show an outlook.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
MYSE has the stronger earnings trend. Trailing diluted EPS is down 273% for ASTS versus MYSE down 147%.
MYSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2021 | -$2.65 | -$1.88 |
| Q2 2021 | -$1.69 | -$0.94 |
| Q1 2021 | -$1.34 | +$1.66 |
| Q4 2020 | -$0.73 | +$4.51 |
MYSE lost $1.25 per share over the past year, a smaller loss than the year before.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over MYSE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS has the edge over MYSE on profitability, with a higher operating margin.
MYSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $37 | -53% |
| Q1 2026 | $73 | -12% |
| Q4 2025 | $61 | -34% |
| Q3 2025 | $328 | +429% |
| Q2 2025 | $78 | -48% |
| Q1 2025 | $83 | -37% |
| Q4 2024 | $92 | -46% |
| Q3 2024 | $62 | -65% |
MYSE's revenue is growing: $37 last quarter, down 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -5817057% | -4013431 points |
| Q1 2026 | -2308863% | -308326 points |
| Q4 2025 | -1872431% | -663521 points |
| Q3 2025 | -390427% | +1606644 points |
| Q2 2025 | -1803626% | -964485 points |
| Q1 2025 | -2000537% | -730752 points |
| Q4 2024 | -1208910% | -373353 points |
| Q3 2024 | -1997071% | -544413 points |
MYSE's operating margin was −5817057% last quarter, down 4013431 points from the same quarter a year ago, near the bottom of its range since 2022.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
MYSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.3M | +$154.3K |
| Q1 2025 | -$1.4M | +$71.9K |
| Q4 2023 | -$1.4M | +$161.4K |
| Q3 2023 | -$2M | +$55.6K |
| Q3 2022 | -$2.1M | -$704.1K |
| Q1 2022 | -$2.3M | -$1.6M |
| Q3 2021 | -$1.3M | -$1M |
| Q1 2021 | -$650.2K | -$379.7K |
MYSE has burned cash in almost every quarter: −$4M over the past year, against −$6M the year before.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over MYSE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
MYSE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +699K shares |
| 1 year | +18% | +771K shares |
| 3 years | +142% | +2.9M shares |
| 5 years | +272% | +3.6M shares |
MYSE has 5M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MYSE Net Leverage
MYSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
MYSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 0.6 | Oversold |
MYSE's weekly RSI is 34 (neutral) and its Stochastic is 1 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
MYSE PE vs Technology Sector
MYSE has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over MYSE on trend strength, trading above more of its moving averages.
MYSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.49 | 29% below |
| 20 week MA | $2.11 | 50% below |
| 50 week MA | $2.05 | 48% below |
| 100 week MA | $2.31 | 54% below |
| 200 week MA | $2.59 | 59% below |
MYSE is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
MYSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $34.2 | $33.9 | -0.9% |
| 2022 | $33.9 | $3.15 | -91% |
| 2023 | $3.15 | $2.87 | -8.9% |
| 2024 | $2.87 | $1.84 | -36% |
| 2025 | $1.84 | $1.87 | +1.6% |
| 2026 YTD | $1.87 | $1.06 | -43% |
MYSE has the edge over ASTS on returns for 2026, with the stronger performance.